These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25253273)

  • 1. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.
    Li G; Verheyen J; Theys K; Piampongsant S; Van Laethem K; Vandamme AM
    Retrovirology; 2014 Sep; 11():79. PubMed ID: 25253273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
    Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
    Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China.
    Zhong P; Kang L; Pan Q; Konings F; Burda S; Ma L; Xue Y; Zheng X; Jin Z; Nyambi P
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):91-101. PubMed ID: 14501800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
    Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
    Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.
    Sutherland KA; Mbisa JL; Cane PA; Pillay D; Parry CM
    J Gen Virol; 2014 Jan; 95(Pt 1):190-200. PubMed ID: 24172906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
    Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
    Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
    PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.
    Neogi U; Rao SD; Bontell I; Verheyen J; Rao VR; Gore SC; Soni N; Shet A; Schülter E; Ekstrand ML; Wondwossen A; Kaiser R; Madhusudhan MS; Prasad VR; Sonnerborg A
    AIDS; 2014 Sep; 28(15):2319-22. PubMed ID: 25102091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.
    Codoñer FM; Peña R; Blanch-Lombarte O; Jimenez-Moyano E; Pino M; Vollbrecht T; Clotet B; Martinez-Picado J; Draenert R; Prado JG
    Sci Rep; 2017 Jun; 7(1):3717. PubMed ID: 28623276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol.
    Nka AD; Teto G; Santoro MM; Ngum Ndze V; Takou D; Dambaya B; Ngoufack Jagni Semengue E; Fabeni L; Perno CF; Colizzi V; Ceccherini-Silberstein F; Fokam J
    PLoS One; 2021; 16(7):e0253587. PubMed ID: 34197501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.
    Kiguoya MW; Mann JK; Chopera D; Gounder K; Lee GQ; Hunt PW; Martin JN; Ball TB; Kimani J; Brumme ZL; Brockman MA; Ndung'u T
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28424286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
    Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
    J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.